| Trial Name | Description |
| IMvoke HN |
Dr. E. Winquist A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the |
| NRG-BN003 |
Dr. Barbara Fisher "not yet open" Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma. |
| NRG HN001 |
Dr. Sara Kuruvilla Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) |
| Window of Opportunity |
Dr. Anthony Nichols A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment with BYL719. |
| ORATOR 2 HN |
Dr. D. Palma A Phase II Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery |
| HN.9 |
Dr. Eric Winquist Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Posi |
| RADIO |
Dr. Sara Kuruvilla "not yet open" Randomized Trial Comparing Low-Dose Weekly to High-Dose Cisplatin Concurrent with Radiation for Locally Advanced Head and Neck Cancer. |
| RTOG1008 |
Dr. Varagur Venkatesan A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High Risk Malignant Salivary Gland Tumors. |
| PDX |
Dr. Anthony Nichols TumorGraft Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer - A Feasibility Study. |
This information is updated by the Clinical Research Unit
